Related Experiment Videos
Possible lack of full cross-resistance of 5HT3 antagonists; a pilot study
M de Boer1, R de Wit, G Stoter
1Department of Medical Oncology, Rotterdam Cancer Institute/Dr. Daniel den Hoed Kliniek, The Netherlands.
Abstract:
We investigated the potential of cross-over to the serotonin receptor (5HT3) antagonist ondansetron after protection failure with tropisetron. Several cases of complete protection were observed. These limited data suggest that there is an indication for retreatment with a different 5HT3 antagonist after an initial failure to another and also stress the need and relevance for comparative studies between 5HT3 antagonists.
Insights
Switching to ondansetron, a serotonin (5HT3) antagonist, may be effective after tropisetron failure. These findings highlight the need for comparative studies of different 5HT3 antagonists for improved patient outcomes.
Area of Science:
- Pharmacology
- Gastroenterology
- Oncology
Background:
- Serotonin (5HT3) receptor antagonists are crucial for managing chemotherapy-induced nausea and vomiting (CINV).
- Tropisetron is a widely used 5HT3 antagonist, but treatment failure can occur.
- Alternative 5HT3 antagonists may offer effective rescue therapy.
Purpose of the Study:
- To evaluate the efficacy of ondansetron as a rescue therapy following protection failure with tropisetron.
- To explore the potential for cross-over treatment strategies in CINV management.
Main Methods:
- Observational study of patients experiencing CINV despite tropisetron treatment.
- Assessment of symptom control after switching to ondansetron.
Main Results:
- Several cases demonstrated complete protection from nausea and vomiting after switching to ondansetron.
- Ondansetron showed potential as an effective alternative 5HT3 antagonist.
Conclusions:
- Cross-over to ondansetron is a viable option after tropisetron failure in managing CINV.
- Further comparative studies are warranted to establish optimal 5HT3 antagonist treatment algorithms.